Overview

To promote effectiveness and minimize possible toxicity, the dosage of certain medications must be adjusted in persons with compromised kidney function.  Failure to enjoin appropriate dosage adjustments in patients with abnormal or rapidly changing kidney function continues to lead to reports of drug toxicity involving a broad array of renally eliminated medications. This updated edition captures nearly 200 new drugs that have been approved by the FDA since the initial publication of Renal Pharmacotherapy. It also covers new evidence that has emerged regarding the need to adjust dosage of certain older medications that are eliminated by the kidneys.  Additionally, it presents new data that are being continuously derived in the areas of patient-specific dose individualization for drugs of all types. Comprehensive, convenient, and evidence-based, this reference closes several identified knowledge gaps and will continue to be the leading collection of dosage recommendations for patients with compromised kidney function.

Full Product Details

Author:   Larry K. Golightly ,  Isaac Teitelbaum ,  Bonita A. Simendinger ,  Tyree H. Kiser
Publisher:   Springer Nature Switzerland AG
Imprint:   Springer Nature Switzerland AG
Edition:   2nd ed. 2021
Weight:   2.541kg
ISBN:  

9783030586492

ISBN 10:   3030586499
Pages:   827
Publication Date:   25 September 2021
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Paperback
Publisher's Status:   Active
Availability:   Manufactured on demand  
We will order this item for you from a manufactured on demand supplier.

Table of Contents

A: Acamprosate to Aztreonam.- B: Bacitracin to Butorphanol.- : Capecitabine to Cycloserine.- D: Dabigatran to Dyphylline.- E: Edetate Calcium Disodium to Exenatide.- F: Famciclovir to Fosfomycin.- H: Hetastarch to Hydroxyurea.- I: Ibandronate to Itraconazole.- K: Kanamycin to Ketorolac.- L: Lacosamide to Lurasidone.- M: Magnesium Citrate to Mycophenolate Mofetil.- N: Nabumetone to Norfloxacin.- O: Ofloxacin to Oxcarbazepine.- P: Paliperidone to Pyridostigmine.- Q: Quinapril to Quinine.- R: Ramipril to Ruxolitinib.- S: Salsalate to Sunitinib.- T: Tadalafil to Trospium.- V: Valacyclovir to Voriconazole.- Z: Zalcitabine to Zonisamide.- Proprietary Name Index.

Reviews

Author Information

Larry K. Golightly, PharmD Clinical Research Pharmacist University of Colorado Hospital Aurora, CO 80045 larry.golightly@uchealth.org   Isaac Teitelbaum, MD, FACP Professor of Medicine Renal Medicine and Hypertension Section, Division of General Internal Medicine University of Colorado School of Medicine and Director, Home Dialysis Program University of Colorado Hospital Aurora, CO 80045 isaac.teitelbaum@cuanschutz.edu   Bonita A. Simendinger, PharmD, BCPS P&T Formulary Compliance Specialist University of Colorado Hospital Aurora, CO 80045 bonita.simendinger@uchealth.org   Tyree H. Kiser, PharmD, BCPS, FCCP, FCCM Professor, Department of Clinical Pharmacy University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences and Critical Care Pharmacy Specialist University of Colorado Hospital Aurora, CO 80045 ty.kiser@cuanschutz.edu   Gerard R. Barber, RPh, MPH, FASHP Clinical Assistant Professor, Department of Clinical Pharmacy University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Aurora, CO 80045 gerard.barber@cuanschutz.edu   Nancy M. Stolpman, PharmD, PhD Associate Clinical Professor University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences and Lead Director of Pharmacy UCHealth Aurora, CO 80045 nancy.stolpman@uchealth.org

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions